文献速递前列腺增生与排尿功能障碍男科与性医学

加拿大可调节经闭孔男性系统治疗前列腺切除术后尿失禁的多中心经验

Canadian Experience with the Adjustable Transobturator Male System for Post-Prostatectomy Incontinence: A Multicenter Study.
PubMed 文献 · J Urol · 2019-10-09

该多中心研究评估了可调节经闭孔男性系统(ATOMS)治疗前列腺切除术后尿失禁的疗效与安全性,纳入8个中心共160例患者,中位随访9.0个月。结果显示总体控尿率为80.0%,改善率为87.8%,患者满意度为86.3%,但既往放疗或抗尿失禁手术者控尿、改善及满意度均较低。

要点

  • ATOMS治疗后中位每日尿垫使用量从术前4片降至0.5片(p<0.001)。
  • 总体控尿率80.0%,改善率87.8%,满意度86.3%。
  • 既往放疗者控尿率62.5% vs 87.9%(p=0.002),满意度69.8% vs 93.2%(p=0.001)。

核心结论

  • 短期来看,ATOMS是治疗前列腺切除术后尿失禁安全有效的装置。
  • 合并放疗或既往抗尿失禁手术的患者对治疗有反应,但控尿、改善或满意的可能性较低。

研究设计与样本

  • 多中心研究,回顾了8个中心接受ATOMS治疗前列腺切除术后尿失禁的男性患者结局,共纳入160例患者,中位随访9.0个月。

主要发现

  • 术前中位每日尿垫使用量为4片(IQR 3-5),术后调整后中位每日尿垫使用量为0.5片(IQR 0-1,p<0.001)。
  • 总体控尿率为80.0%,改善率为87.8%。
  • 70.1%的患者接受了平均2.4±2.7次调整(IQR 0-16)。
  • 患者满意度为86.3%,22.3%发生任何级别的90天并发症,7例(4.4%)发生Clavien III级并发症,主要与注射端口相关。
  • 有放疗史的患者控尿率较低(62.5% vs 87.9%,p=0.002),改善率较低(77.1% vs 92.6%,p=0.02),满意度较低(69.8% vs 93.2%,p=0.001);既往抗尿失禁手术患者的控尿率、改善率和满意度分别为57.7%、73.1%和69.6%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the efficacy and safety profile of the ATOMS® (Adjustable Transobturator Male System) for post-prostatectomy incontinence in a multicenter North American setting. MATERIALS AND METHODS: We reviewed outcomes from 8 centers in men who underwent treatment of post-prostatectomy incontinence with an ATOMS. Primary study outcomes were pad changes and continence, defined as requiring 1.0 or 0 pad postoperatively in patients who required 2.0 or more pads preoperatively and 0 pad in those who required more than 1.0 or 2.0 pads preoperatively. Secondary outcomes included improvement, 90-day complications and patient satisfaction. RESULTS: A total of 160 patients were enrolled in study with a median followup of 9.0 months. Preoperative median pad use was 4 per day (IQR 3-5). Of the patients 36.3% reported severe preoperative incontinence, 31.3% received prior radiotherapy and 16.3% underwent previous incontinence surgery. Median postoperative pad use after adjustments was 0.5 per day (IQR 0-1, p <0.001). The overall continence rate was 80.0% with improvement in 87.8% of cases. Of the patients 70.1% underwent a mean ± SD of 2.4 ± 2.7 adjustments (IQR 0-16). The patient satisfaction rate was 86.3%, 22.3% experienced 90-day complications of any grade and 7 (4.4%) experienced Clavien III complications primarily related to the injection port. Patients with a history of radiotherapy were less likely to be continent (62.5% vs 87.9%, p=0.002), improved (77.1% vs 92.6%, p=0.02) or satisfied (69.8% vs 93.2%, p=0.001). Similarly patients with previous incontinence surgery had lower rates of continence, improvement and satisfaction (57.7%, 73.1% and 69.6%, respectively). CONCLUSIONS: In the short term the ATOMS is a safe and efficacious device to treat post-prostatectomy incontinence. Patients with concurrent radiotherapy and previous incontinence surgery respond to treatment but are less likely to be continent, improved or satisfied.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Doiron RC, Saavedra A, Haines T, et al. Canadian Experience with the Adjustable Transobturator Male System for Post-Prostatectomy Incontinence: A Multicenter Study. J Urol. 2019. PMID: 31251715. doi:10.1097/JU.0000000000000420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。